This is an open label, non-randomised, multicentre phase 1-2 study with a fixed dose of
Taxotere in combination with Xeloda which is dose escalated during the first phase of the
study (modified Fibonacci design) and fixed during the second phase.
The primary objective of the phase 1 part is to define the dose recommended for the Phase II
part of the study. The primary objective is to determine the response rate.